Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Weinheim, Germany Clinical Trials

A listing of Weinheim, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (28) clinical trials

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or was refractory to the standard ...

Phase

8.34 miles

Learn More »

A First-In-Human Study to Evaluate Safety Tolerability Reactogenicity and Immunogenicity of JNJ-64300535 a DNA Vaccine Administered by Electroporation-Mediated Intramuscular Injection in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed

The purpose of this study is to evaluate the safety, tolerability, and reactogenicity of escalating doses of JNJ-64300535 delivered via electroporation-mediated intramuscular injection in nucleos(t)ide analogs (NA)-treated chronic hepatitis B (CHB) participants.

Phase

8.34 miles

Learn More »

A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male and female subjects following oral administration of multiple rising doses over 4 weeks.

Phase

8.34 miles

Learn More »

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198

To investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of multiple rising doses per day over 14 days and to investigate the food effect on the relative bioavailability of BI 764198.

Phase

8.34 miles

Learn More »

Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer

OBJECTIVES: - Primary - To assess the safety and tolerability of daily cilengitide by determining its dose-limiting toxicity and maximum-tolerated dose when combined with concomitant fractionated whole-brain radiation therapy in patients with brain metastases from lung cancer. - Secondary - To collect evidence of the best overall response rate, overall ...

Phase

8.34 miles

Learn More »

Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema

Patients with diabetic retinopathy suffer from visual acuity loss caused by diabetic macular edema. Intravitreal injected Triamcinolone Acetonide (steroid) reduces macular edema and increases visual acuity. The duration of its effect is however limited. Therefore, several injections are necessary. In this study a dosage dependency of triamcinolone acetonide (high dosage ...

Phase

8.34 miles

Learn More »

Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma

The Lipo-MERIT vaccine consists of the four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 that are optimised to induce antigen-specific CD8+ and CD4+ T cell responses against four selected malignant melanoma-associated antigens respectively. In this study, naked RNA DPs will be formulated with liposomes to form ...

Phase

8.34 miles

Learn More »

A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Na ve Higher-Risk Myelodysplastic Syndromes (MDS)

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in subjects with treatment-nave higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Phase

8.34 miles

Learn More »

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).

Phase

8.34 miles

Learn More »

Study to Assess Safety Tolerability Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies

Phase

9.15 miles

Learn More »